Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD

被引:30
|
作者
Sun, D-Q [1 ,2 ]
Ye, F-Z [3 ,4 ]
Kani, H. T. [5 ]
Yang, J-R [6 ]
Zheng, K., I [3 ]
Zhang, H-Y [7 ]
Targher, G. [8 ,9 ]
Byrne, C. D. [10 ]
Chen, Y-P [3 ,11 ,13 ]
Yuan, W-J [2 ]
Yilmaz, Y. [5 ,12 ]
Zheng, M-H [3 ,11 ]
机构
[1] Nanjing Med Univ, Affiliated Wuxi 2 Peoples Hosp, Dept Nephrol, Wuxi, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Shanghai Gen Hosp, Dept Nephrol, Shanghai, Peoples R China
[3] Wenzhou Med Univ, Affiliated Hosp 1, NAFLD Res Ctr, Dept Hepatol, 2 Fuxue Lane, Wenzhou 325000, Peoples R China
[4] Wenzhou Med Univ, Sch Clin Med Sci 1, Wenzhou, Peoples R China
[5] Marmara Univ, Sch Med, Dept Gastroenterol, TR-34662 Istanbul, Turkey
[6] Wenzhou Med Univ, Affiliated Hosp 1, Dept Clin Lab, Wenzhou, Peoples R China
[7] Sun Yat Sen Univ, Sch Biomed Engn, Guangzhou, Peoples R China
[8] Univ Verona, Dept Med, Div Endocrinol Diabet & Metab, Verona, Italy
[9] Azienda Osped Univ Integrata Verona, Verona, Italy
[10] Univ Hosp Southampton, Southampton Gen Hosp, Southampton Natl Inst Hlth Res, Biomed Res Ctr, Southampton, Hants, England
[11] Wenzhou Med Univ, Inst Hepatol, Wenzhou, Peoples R China
[12] Marmara Univ, Inst Gastroenterol, Istanbul, Turkey
[13] Key Lab Diag & Treatment Dev Chron Liver Dis Zhej, Wenzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Early kidney dysfunction; Liver fibrosis; Liver stiffness measurement; Non-alcoholic fatty liver disease; INSULIN-RESISTANCE; DISEASE; RISK; MICROALBUMINURIA; STEATOHEPATITIS; STRESS;
D O I
10.1016/j.diabet.2019.11.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim. - The association between Liver fibrosis (LF), as assessed by either histology or Liver stiffness measurement (LSM), and the presence of Early kidney dysfunction (EKD) was investigated in this study, as was also the diagnostic performance of LSM for identifying the presence of EKD in patients with Nonalcoholic fatty liver disease (NAFLD). Materials and methods. - A total of 214 adults with non-cirrhotic biopsy-proven NAFLD were recruited from two independent medical centres. Their histological stage of LF was quantified using Brunt's criteria. Vibration-controlled Transient elastography (TE), using M-p robe ( Fib roScan (R)) ultrasound, was performed in 154 patients and defined as significant when LSM was >= 8.0 kPa. EKD was defined as the presence of microalbuminuria with an estimated glomerular filtration rate >= 60 mL/min/1.73 m(2). Logistic regression modelling was used to estimate the likelihood of having EKD with NAFLD (LSM-EKD model). Results. - The prevalence of EKD was higher in patients with vs without LF on histology (22.14% vs 4.82%, respectively; P < 0.001) and, similarly, EKD prevalence was higher in patients with LSM >= 8.0 kPa vs LSM < 8.0 kPa (23.81% vs 6.59%, respectively; P < 0.05). The area under the ROC curve of the LSM-EKD model for identifying EKD was 0.80 (95% CI: 0.72-0.89). LF detected by either method was associated with EKD independently of established renal risk factors and potential confounders. Conclusion. - LF was independently associated with EKD in patients with biopsy-proven NAFLD. Thus, TE-measured LSM, a widely used technique for quantifying LF, can accurately identify those patients with NAFLD who are at risk of having EKD. (C) 2019 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:288 / 295
页数:8
相关论文
共 50 条
  • [21] The Serum Biomarkers of Cardiovascular Disease Are Elevated in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) With Advanced Fibrosis and Histologically-Proven Non-alcoholic Steatohepatitis (NASH)
    Elsheikh, Elzafir
    Tran, Henry A.
    Karrar, Azza
    Estep, Michael
    Felix, Sean C.
    Jeffers, Thomas
    Younoszai, Zahra
    Racila, Andrei
    Fang, Yun
    Elsheikh, Munkhzul
    Lam, Brian P.
    Abdul-Al, Hala
    Goodman, Zachary
    Gerber, Lynn
    Younossi, Zobair M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S538 - S539
  • [22] Longitudinal prognostic value of the most common algorithms for fibrosis in non-alcoholic fatty liver disease. An international study in non-cirrhotic, biopsy-proven patients
    Younes, R.
    Rosso, C.
    Garcia Blanco, M. J.
    Petta, S.
    Miele, L.
    Liguori, A.
    Francione, P.
    Fracanzani, A.
    Valenti, L.
    Anstee, Q. M.
    Bugianesi, E.
    DIGESTIVE AND LIVER DISEASE, 2019, 51 : E5 - E5
  • [23] NON-INVASIVE BIOMARKERS OF COLLAGEN TYPE III AND VI REMODELLING ARE ELEVATED IN LUPUS NEPHRITIS PATIENTS AND ARE ASSOCIATED WITH HISTOLOGICALLY PROVEN KIDNEY FIBROSIS
    Genovese, Federica
    Akhgar, Ahmad
    Farris, Alton B., III
    Lim, Sam S.
    Battle, Monica
    Cobb, Jason
    Sinibaldi, Dominic
    Karsdal, Morten A.
    White, Wendy I.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [24] AMONG PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) PRESENCE OF FATIGUE IS ASSOCIATED WITH HIGHER MORTALITY
    Golabi, Pegah
    Paik, James M.
    Henry, Linda
    Nader, Fatema
    Gerber, Lynn H.
    Younossi, Zobair M.
    HEPATOLOGY, 2021, 74 : 368A - 368A
  • [25] Liver clear cell foci and viral infection are associated with non-cirrhotic, non-fibrolamellar hepatocellular carcinoma in young patients from South America
    Cano, Luis
    Cerapio, Juan Pablo
    Ruiz, Eloy
    Marchio, Agnes
    Turlin, Bruno
    Casavilca, Sandro
    Taxa, Luis
    Marti, Guillaume
    Deharo, Eric
    Pineau, Pascal
    Bertani, Stephane
    SCIENTIFIC REPORTS, 2018, 8
  • [26] Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease
    Giovanni Alejandro Salgado Alvarez
    Samanta Mayanin Pinto Galvez
    Uriel Garcia Mora
    Ana Delfina Cano Contreras
    Cristina Durán Rosas
    Bryan Adrián Priego-Parra
    Arturo Triana Romero
    Mercedes Amieva Balmori
    Federico Roesch Dietlen
    Sophia Eugenia Martinez Vazquez
    Ines Osvely Mendez Guerrero
    Luis Alberto Chi-Cervera
    Raúl Bernal Reyes
    Leonardo Alberto Martinez Roriguez
    Maria Eugenia Icaza Chavez
    Jose Maria Remes Troche
    World Journal of Hepatology, 2022, (08) : 1633 - 1642
  • [27] Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease
    Alvarez, Giovanni Alejandro Salgado
    Galvez, Samanta Mayanin Pinto
    Mora, Uriel Garcia
    Contreras, Ana Delfina Cano
    Rosas, Cristina Duran
    Priego-Parra, Bryan Adrian
    Romero, Arturo Triana
    Balmori, Mercedes Amieva
    Dietlen, Federico Roesch
    Vazquez, Sophia Eugenia Martinez
    Guerrero, Ines Osvely Mendez
    Chi-Cervera, Luis Alberto
    Bernal Reyes, Raul
    Roriguez, Leonardo Alberto Martinez
    Chavez, Maria Eugenia Icaza
    Troche, Jose Maria Remes
    WORLD JOURNAL OF HEPATOLOGY, 2022, 14 (08) : 1633 - 1642
  • [28] Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
    Abdelhameed, Farah
    Kite, Chris
    Lagojda, Lukasz
    Dallaway, Alexander
    Chatha, Kamaljit Kaur
    Chaggar, Surinderjeet S.
    Dalamaga, Maria
    Kassi, Eva
    Kyrou, Ioannis
    Randeva, Harpal S.
    CURRENT OBESITY REPORTS, 2024, 13 (03): : 510 - 531
  • [29] Non-Alcoholic Fatty Liver Disease (NAFLD) Is Associated With an Accelerated Rate of Decline of Kidney Function in Type 2 Diabetic Patients
    Higa, Mariko
    Doi, Ayano
    Yoshida, Eiko
    Yoshifuji, Ayumu
    Yamashita, Kaoru
    Ichijo, Takamasa
    Ouchi, Hiromi
    DIABETES, 2013, 62 : A606 - A606
  • [30] The association between non-invasive tests of liver fibrosis and early diastolic dysfunction in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
    Amato, F.
    Armandi, A.
    Andreis, A.
    Bellettini, M.
    Lorusso, F.
    Gjini, K.
    Marano, M.
    Vaira, L.
    Rosso, C.
    Caviglia, G. P.
    Guariglia, M.
    Dileo, E.
    Castagno, D.
    Alunni, G.
    De Ferrari, G. M.
    Bugianesi, E.
    DIGESTIVE AND LIVER DISEASE, 2025, 57